US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
TSLA
$370.59
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Silo Pharma, Inc. - Common Stock
(NQ:
SILO
)
1.458
-0.002 (-0.14%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silo Pharma, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent
↗
June 21, 2023
Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted...
Via
Benzinga
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent
June 21, 2023
New patent expands Company’s intellectual property and technology rights portfolio
From
Silo Pharma, Inc.
Via
GlobeNewswire
Why Advanced Health Intelligence Shares Are Trading Higher By 111%; Here Are 20 Stocks Moving Premarket
↗
June 21, 2023
Gainers Advanced Health Intelligence Ltd. (NASDAQ: AHI) shares gained 110.8% to $1.56 in pre-market trading after the company signed a Letter of Intention with UAE-Based e-script medicine management...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
↗
June 21, 2023
It's time to start off the day with a breakdown of the biggest pre-market stock movers worth watching on Wednesday morning!
Via
InvestorPlace
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
↗
June 13, 2023
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with...
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
June 13, 2023
Via
Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 13, 2023
Via
Benzinga
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
June 13, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate, Share Profile on Webull Platform
June 02, 2023
Via
Investor Brand Network
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
June 02, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement to Further Study Novel Joint Homing Peptide
May 30, 2023
Via
Investor Brand Network
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
May 30, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
↗
May 15, 2023
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths...
Via
Benzinga
Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
↗
May 10, 2023
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and...
Via
Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
ENGLEWOOD CLIFFS, NJ – May 9, 2023 – Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Via
FinancialNewsMedia
Topics
Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
May 09, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
↗
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
April 24, 2023
Via
Investor Brand Network
Silo Pharma to Present at Psychedelic Drug Development Conference
April 24, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds
↗
April 20, 2023
Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
April 19, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023
ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic...
Via
FinancialNewsMedia
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
April 19, 2023
Data to Support Alzheimer’s Study
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
↗
April 05, 2023
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...
Via
Benzinga
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
March 28, 2023
Via
Investor Brand Network
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition
↗
March 27, 2023
Biopharma company Silo Pharma Inc.
Via
Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
March 27, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
March 27, 2023
From
Silo Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
